---
layout: post
title: "Determination That ZOFRAN ODT (Ondansetron) Orally Disintegrating Tablets, 4 Milligrams and 8 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 18:57:14 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-22844
original_published: 2023-10-17 00:00:00 +0000
significance: 8.00
---

# Determination That ZOFRAN ODT (Ondansetron) Orally Disintegrating Tablets, 4 Milligrams and 8 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** October 17, 2023 00:00 UTC
**Document Number:** 2023-22844

## Summary

The Food and Drug Administration (FDA or the Agency) has determined that ZOFRAN ODT (ondansetron) orally disintegrating tablets, 4 milligrams (mg) and 8 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/10/17/2023-22844/determination-that-zofran-odt-ondansetron-orally-disintegrating-tablets-4-milligrams-and-8)
- API: https://www.federalregister.gov/api/v1/documents/2023-22844

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
